Search Results
Your search for ,yes matches 614 pages
Showing 1 - 50What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
A mobile health tool designed specifically for adolescent and young adult (AYA) breast cancer survivors significantly improved overall quality of life and reduced symptoms related to vaginal and arm problems when compared with usual care, according to the results of a multicenter randomized trial...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making
This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...
Understanding Accelerated Aging in Survivors of Childhood Cancers
Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven
Cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte therapy are transforming outcomes for patients with cancer, particularly in the relapsed or refractory setting. “We’re seeing outstanding response rates in patients with B-cell malignancies...
Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
“Knowledge is like a lion; it cannot be gently embraced.” –South African Proverb Long-term efficacy and safety confirm that a hypomethylating agent and venetoclax is an improvement in the standard of care for patients with AML who are not eligible for intensive chemotherapy because of advanced age...
Local Excision May Be Feasible in Patients With Low Rectal Adenocarcinoma
Chemotherapy followed by local excision may be effective in patients with node-negative low rectal adenocarcinoma, according to new findings presented by Buettner et al at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. Background The current standard of care among most patients with...
Conundrums in Treating HER2-Positive Early Breast Cancer
Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer
The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...
Only Half of Young Adults With Cancer Are Told of Fertility Preservation Options by Their Providers: Strategies for Improving That Number
Each year in the United States, approximately 90,000 adolescents and young adults (AYAs), defined as those between the ages of 15 and 39, are diagnosed with cancer, and about 9,300 die of the disease.1 Worldwide, the number of new cases of cancer in this age population tops 1,300,200—an increase of ...
Addition of Palbociclib to Standard Therapy in Metastatic Hormone Receptor–Positive, HER2-Positive Breast Cancer
Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with hormone receptor (HR)-positive,...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
How Functional and Genomic Precision Medicine Are Getting Closer to Matching Each Patient to the Right Therapy
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer
Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology Jean-Marc Classe, MD, PhD, Head of the Oncological Surgery Department at the Institut de Cancérologie de l’Ouest, Saint Herblain, France, and colleagues, the addition of hyperthermic...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab ...
How End-of-Life Dreams and Visions Are Bringing Comfort to Dying Patients
Just weeks or even days or hours away from death, the majority of conscious terminally ill patients often experience growth and meaning in their lives and the absence of fear through end-of-life dreams and visions, according to research by Christopher W. Kerr, MD, PhD. Dr. Kerr is Chief Executive...
Raising Awareness of the Health Consequences of Alcohol Consumption During and After a Cancer Diagnosis
In 2023, the World Health Organization (WHO) declared that “no level of alcohol consumption is safe for our health.”1 The warning came decades after the International Agency for Research on Cancer classified alcohol as a Group 1 carcinogen, which is the highest risk group, and also includes...
FDA Approves Inavolisib Combination in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) approved the PI3K inhibitor inavolisib (Itovebi) with the CDK4/6 inhibitor palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, as...
Breast and Ovarian Cancers May Be Linked to Thousands of RAD51C Gene Variants
Researchers have identified thousands of genetic changes in a gene that may increase the risk of developing breast and ovarian cancers, according to a recent study published by Olvera-León et al in Cell. The findings may pave the way for better risk assessment and more personalized care. ...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...
Early-Onset Colorectal Cancer: Rurality and Poverty May Be Linked to Lower Survival
Patients with early-onset colorectal cancer living in rural vs urban areas were found to have a lower likelihood of 5-year survival, with persistent poverty compounding this association in some age groups, according to an analysis published in a research letter by Tsai et al in JAMA Network Open....
How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life
Several years ago, a visit to the National Air and Space Museum in Washington, DC, so fascinated and inspired Mace L. Rothenberg, MD, FASCO, about the history of flight, he wondered why there was not a similar museum showcasing the past and present achievements in science and medicine. The result...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
Improving AML Outcomes: Testing for MRD Prior to Bone Marrow Transplant
Testing for measurable residual disease (MRD) prior to bone marrow transplant may be effective and practical in patients in remission after receiving treatment for acute myeloid leukemia (AML), according to a recent study published by Dillon et al in JAMA Oncology. Study Methods and Results In the...
Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
Prophylactic Oral Vancomycin May Prevent C Difficile Infections, Raise Risk of Gram-Negative Bacteremia in Stem Cell Transplant Recipients
Preventive use of the oral antibiotic vancomycin may be effective at reducing the risk of Clostridioides difficile infections but may increase the risk of gram-negative bacteremia in stem cell transplant recipients, according to new findings presented by Vartanov et al at the 2024 Tandem Meetings:...
Sleep Apnea May Be Prevalent Among Patients With Cancer at High Risk of Congestive Heart Failure
Sleep apnea may be prevalent among patients who are at higher risk of developing congestive heart failure from cancer therapy, according to new findings presented by Das et al at the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient course. Background...
Expert Point of View: Rory M. Shallis, MD
Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...
Presence of MRD After Chemotherapy May Predict Benefit From Donor Transplant in NPM1-Mutated AML
Among patients who have acute myeloid leukemia (AML) with genetic mutations in NPM1, those with no residual leukemia cells in the blood based on high-sensitivity testing after two cycles of chemotherapy achieved high rates of overall survival at 3 years and saw no additional survival benefit from...
Expert Point of View: Benjamin Besse, MD, PhD
“In patients with exon 20–mutated non–small cell lung cancer, PAPILLON established a new standard of care with amivantamab-vmjw and chemotherapy,” according to study discussant, Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, and Head of Clinical Research...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present
I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting
According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...
Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer
It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, ...
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
With longer-term follow-up, adjuvant nivolumab continued to demonstrate improved disease-free survival, non–urothelial tract recurrence–free survival, and distant metastasis–free survival vs placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after surgery,...
How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors
As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...
Expert Point of View: Barbara Pistilli, MD
The invited discussant of the study by Bar et al, Barbara Pistilli, MD, Head of the Breast Cancer Unit at Gustave Roussy Cancer Center, Villejuif, France, noted that third-generation antibody-drug conjugates, such as fam-trastuzumab deruxtecan-nxki (T-DXd), are showing activity across a wide range ...
